Home > Journals > Minerva Endocrinology > Past Issues > Minerva Endocrinologica 2003 March;28(1) > Minerva Endocrinologica 2003 March;28(1):27-38

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  GROWTH HORMONE: CLINICAL ASPECTS 

Minerva Endocrinologica 2003 March;28(1):27-38

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: Italian

Genetics basis of pituitary tumors

Spada A., Lania A.


PDF


In the last few years molecular biology technologies have provided important insights into mechanisms possibly involved in pituitary tumor formation. Several evidences indicate that the majority of pituitary adenomas is monoclonal, thus implying that they derive from the replication of a single mutant cell. In about 30-40% of GH-secreting adenomas mutations at codon 201 and 227 of GNAS1 gene that codes for the Gs alpha subunit have been identified. These mutations, named gsp for Gs protein, cause the constitutive, hormone-independent, activation of adenylyl cyclase and consequent overproduction of cAMP, that is mitogenic in somatotropes. Screening studies carried out on large series of acromegalic patients carrying tumors with or without gsp oncogene failed to detect clinical differences between the two groups. The existence of mechanisms induced by gsp mutations and able to counteract the mitogenic potential of this oncogene has been hypothesized. In particular, several events including the low expression of mutant Gs, the induction of phosphodiesterases, that are involved in cAMP degradation, and of the inducible cAMP early repressor (ICER) that represses cAMP induced gene expression, together with a high sensitivity to somatostatin have been characterized in gsp positive tumors. As far as the loss of oncosuppressors is concerned, no mutations of these genes have been so far reported, while they are frequently expressed at low levels in pituitary tumors. However, the nature of initiating and promoting events involved in tumor formation remains to be clarified in the majority of pituitary tumors.

top of page